DDInter1702 DDInter1610
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Sorafenib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rivastigmine
Sorafenib {u} (Compound) upregulates {v} (Gene) CCNH
CCNH {u} (Gene) is downregulated by {v} (Compound) Rivastigmine
Sorafenib {u} (Compound) downregulates {v} (Gene) ITGB1BP1
ITGB1BP1 {u} (Gene) is downregulated by {v} (Compound) Rivastigmine
Sorafenib {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Rivastigmine
Sorafenib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pyridostigmine
Pyridostigmine {u} (Compound) resembles {v} (Compound) Rivastigmine
Sorafenib {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Tapentadol
Tapentadol {u} (Compound) resembles {v} (Compound) Rivastigmine
Sorafenib {u} (Compound) upregulates {v} (Gene) CCNH
CCNH {u} (Gene) is downregulated by {v} (Disease) Parkinson's disease
Parkinson's disease {u} (Disease) is palliated by {v} (Compound) Rivastigmine
Sorafenib {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Pyridostigmine
Pyridostigmine {u} (Compound) resembles {v} (Compound) Rivastigmine
Sorafenib {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Tapentadol
Tapentadol {u} (Compound) resembles {v} (Compound) Rivastigmine
Sorafenib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Rivastigmine
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rivastigmine (Compound)
Sorafenib (Compound) upregulates CCNH (Gene) and CCNH (Gene) is downregulated by Rivastigmine (Compound)
Sorafenib (Compound) downregulates ITGB1BP1 (Gene) and ITGB1BP1 (Gene) is downregulated by Rivastigmine (Compound)
Sorafenib (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Rivastigmine (Compound)
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pyridostigmine (Compound) and Pyridostigmine (Compound) resembles Rivastigmine (Compound)
Sorafenib (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tapentadol (Compound) and Tapentadol (Compound) resembles Rivastigmine (Compound)
Sorafenib (Compound) upregulates CCNH (Gene) and CCNH (Gene) is downregulated by Parkinson's disease (Disease) and Parkinson's disease (Disease) is palliated by Rivastigmine (Compound)
Sorafenib (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Pyridostigmine (Compound) and Pyridostigmine (Compound) resembles Rivastigmine (Compound)
Sorafenib (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Tapentadol (Compound) and Tapentadol (Compound) resembles Rivastigmine (Compound)
Sorafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Rivastigmine (Compound)